For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Docetaxel | Docetaxel (Taxotere): Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters. | None | None | 6 | 19 | 17 | 19 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Weights Loss | None | General disorders | None | View |
| Upper GI Bleed | None | Gastrointestinal disorders | None | View |
| Hematochezia | None | Gastrointestinal disorders | None | View |
| Neuropathy | None | Nervous system disorders | None | View |
| Thrombocytopenia | None | Blood and lymphatic system disorders | None | View |
| Anemia | None | Blood and lymphatic system disorders | None | View |
| Neutropenia | None | Blood and lymphatic system disorders | None | View |
| Rectal | None | Gastrointestinal disorders | None | View |
| Other | None | General disorders | None | View |
| Urinary Frequency/Urgency | None | Renal and urinary disorders | None | View |
| Fatigue | None | General disorders | None | View |
| Bowel Frequency/Urgency | None | Gastrointestinal disorders | None | View |